Which has higher valuation & earnings, LIVN or ZBH?

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.14 -$242.47M $1.95 40.72 Zimmer Biomet $8.23B 2.12 $705.20M $3.85 23.41

Is LIVN or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Zimmer Biomet's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media favor LIVN or ZBH?

In the previous week, Zimmer Biomet had 12 more articles in the media than LivaNova. MarketBeat recorded 15 mentions for Zimmer Biomet and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Zimmer Biomet's score of 1.05 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zimmer Biomet 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LIVN or SOLV?

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.14 -$242.47M $1.95 40.72 Solventum $8.33B 1.63 $1.56B $8.16 9.61

Is LIVN or SOLV more profitable?

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Solventum 17.33% 23.51% 7.63%

Does the media favor LIVN or SOLV?

In the previous week, Solventum had 7 more articles in the media than LivaNova. MarketBeat recorded 10 mentions for Solventum and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Solventum's score of 1.25 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solventum 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, LIVN or SNN?

Smith & Nephew SNATS has higher revenue and earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.14 -$242.47M $1.95 40.72 Smith & Nephew SNATS $6.16B 2.11 $625M N/A N/A

Does the media favor LIVN or SNN?

In the previous week, LivaNova and LivaNova both had 3 articles in the media. LivaNova's average media sentiment score of 1.68 beat Smith & Nephew SNATS's score of 0.96 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, LIVN or PEN?

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.14 -$242.47M $1.95 40.72 Penumbra $1.40B 8.88 $177.69M $4.34 73.03

Is LIVN or PEN more profitable?

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 7.48% 16.48% 7.59% Penumbra 11.76% 10.87% 8.45%

Does the media prefer LIVN or PEN?

In the previous week, LivaNova and LivaNova both had 3 articles in the media. LivaNova's average media sentiment score of 1.68 beat Penumbra's score of 1.07 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Penumbra 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GKOS or LIVN?

Glaukos has higher earnings, but lower revenue than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 18.19 -$187.69M -$3.28 N/A LivaNova $1.39B 3.14 -$242.47M $1.95 40.72

Is GKOS or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% LivaNova 7.48% 16.48% 7.59%

Does the media refer more to GKOS or LIVN?

In the previous week, Glaukos had 4 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Glaukos and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Glaukos' score of 0.42 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

LivaNova (LIVN) Competitors

$79.41 +0.29 (+0.37%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$79.42 +0.01 (+0.01%)

As of 07/15/2026 04:26 PM Eastern

Compare

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy LivaNova stock or one of its competitors? MarketBeat compares LivaNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LivaNova include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does LivaNova compare to Zimmer Biomet?

LivaNova (NASDAQ:LIVN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Zimmer Biomet has a net margin of 9.05% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Zimmer Biomet	9.05%	13.24%	7.28%

Zimmer Biomet has higher revenue and earnings than LivaNova. Zimmer Biomet is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.14	-$242.47M	$1.95	40.72
Zimmer Biomet	$8.23B	2.12	$705.20M	$3.85	23.41

In the previous week, Zimmer Biomet had 12 more articles in the media than LivaNova. MarketBeat recorded 15 mentions for Zimmer Biomet and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Zimmer Biomet's score of 1.05 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zimmer Biomet	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova currently has a consensus price target of $81.38, indicating a potential upside of 2.47%. Zimmer Biomet has a consensus price target of $100.70, indicating a potential upside of 11.73%. Given Zimmer Biomet's higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zimmer Biomet	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Zimmer Biomet beats LivaNova on 9 of the 17 factors compared between the two stocks.

How does LivaNova compare to Solventum?

LivaNova (NASDAQ:LIVN) and Solventum (NYSE:SOLV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

LivaNova presently has a consensus target price of $81.38, suggesting a potential upside of 2.47%. Solventum has a consensus target price of $81.91, suggesting a potential upside of 4.50%. Given Solventum's higher possible upside, analysts clearly believe Solventum is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Solventum	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

97.6% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to LivaNova's net margin of 7.48%. Solventum's return on equity of 23.51% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Solventum	17.33%	23.51%	7.63%

Solventum has higher revenue and earnings than LivaNova. Solventum is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.14	-$242.47M	$1.95	40.72
Solventum	$8.33B	1.63	$1.56B	$8.16	9.61

In the previous week, Solventum had 7 more articles in the media than LivaNova. MarketBeat recorded 10 mentions for Solventum and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Solventum's score of 1.25 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solventum	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solventum beats LivaNova on 8 of the 15 factors compared between the two stocks.

How does LivaNova compare to Smith & Nephew SNATS?

LivaNova (NASDAQ:LIVN) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Smith & Nephew SNATS has higher revenue and earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.14	-$242.47M	$1.95	40.72
Smith & Nephew SNATS	$6.16B	2.11	$625M	N/A	N/A

LivaNova has a net margin of 7.48% compared to Smith & Nephew SNATS's net margin of 0.00%. LivaNova's return on equity of 16.48% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Smith & Nephew SNATS	N/A	N/A	N/A

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, LivaNova and LivaNova both had 3 articles in the media. LivaNova's average media sentiment score of 1.68 beat Smith & Nephew SNATS's score of 0.96 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Smith & Nephew SNATS	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova currently has a consensus price target of $81.38, indicating a potential upside of 2.47%. Smith & Nephew SNATS has a consensus price target of $30.93, indicating a potential upside of 0.49%. Given LivaNova's stronger consensus rating and higher possible upside, equities research analysts clearly believe LivaNova is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

LivaNova beats Smith & Nephew SNATS on 10 of the 13 factors compared between the two stocks.

How does LivaNova compare to Penumbra?

LivaNova (NASDAQ:LIVN) and Penumbra (NYSE:PEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

LivaNova currently has a consensus price target of $81.38, indicating a potential upside of 2.47%. Penumbra has a consensus price target of $360.33, indicating a potential upside of 13.68%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60
Penumbra	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Penumbra has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.14	-$242.47M	$1.95	40.72
Penumbra	$1.40B	8.88	$177.69M	$4.34	73.03

Penumbra has a net margin of 11.76% compared to LivaNova's net margin of 7.48%. LivaNova's return on equity of 16.48% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
Penumbra	11.76%	10.87%	8.45%

LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.4% of LivaNova shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, LivaNova and LivaNova both had 3 articles in the media. LivaNova's average media sentiment score of 1.68 beat Penumbra's score of 1.07 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Penumbra	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Penumbra beats LivaNova on 9 of the 15 factors compared between the two stocks.

How does LivaNova compare to Glaukos?

Glaukos (NYSE:GKOS) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Glaukos has higher earnings, but lower revenue than LivaNova. Glaukos is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	18.19	-$187.69M	-$3.28	N/A
LivaNova	$1.39B	3.14	-$242.47M	$1.95	40.72

Glaukos presently has a consensus price target of $151.77, suggesting a potential downside of 3.46%. LivaNova has a consensus price target of $81.38, suggesting a potential upside of 2.47%. Given LivaNova's higher possible upside, analysts plainly believe LivaNova is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.60

LivaNova has a net margin of 7.48% compared to Glaukos' net margin of -34.34%. LivaNova's return on equity of 16.48% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
LivaNova	7.48%	16.48%	7.59%

In the previous week, Glaukos had 4 more articles in the media than LivaNova. MarketBeat recorded 7 mentions for Glaukos and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.68 beat Glaukos' score of 0.42 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Glaukos has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

LivaNova beats Glaukos on 9 of the 16 factors compared between the two stocks.

Get LivaNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIVN vs. The Competition

Export

Metric	LivaNova	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.35B	$7.43B	$6.78B	$12.56B
Dividend Yield	N/A	1.34%	2.68%	9.45%
P/E Ratio	40.72	50.74	27.08	24.35
Price / Sales	3.14	79.06	487.23	76.01
Price / Cash	16.36	26.20	48.63	60.00
Price / Book	3.61	7.21	10.82	6.31
Net Income	-$242.47M	$162.30M	$3.59B	$331.55M
7 Day Performance	-3.77%	-0.75%	-1.80%	-0.71%
1 Month Performance	-0.09%	0.12%	3.71%	0.16%
1 Year Performance	84.72%	8.24%	27.41%	19.66%

LivaNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIVN LivaNova	2.3318 of 5 stars	$79.41 +0.4%	$81.38 +2.5%	+82.8%	$4.35B	$1.39B	40.72	3,300	Positive News Analyst Forecast
ZBH Zimmer Biomet	3.7169 of 5 stars	$94.09 +3.0%	$102.33 +8.8%	-4.1%	$17.67B	$8.23B	24.44	17,000
SOLV Solventum	3.6813 of 5 stars	$77.48 +1.0%	$83.67 +8.0%	+6.4%	$13.28B	$8.33B	9.50	20,000	News Coverage Positive News Analyst Forecast
SNN Smith & Nephew SNATS	2.0828 of 5 stars	$31.08 +1.2%	$30.93 -0.5%	+4.9%	$12.97B	$6.16B	N/A	16,988
PEN Penumbra	2.2603 of 5 stars	$318.61 +0.2%	$360.33 +13.1%	+34.1%	$12.51B	$1.45B	73.41	4,700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIVN) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LivaNova (LIVN) Competitors

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does LivaNova compare to Zimmer Biomet?

Summary

How does LivaNova compare to Solventum?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Summary

How does LivaNova compare to Penumbra?

Summary

How does LivaNova compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LivaNova (LIVN) Competitors

LIVN vs. ZBH, SOLV, SNN, PEN, and GKOS

How does LivaNova compare to Zimmer Biomet?

Do institutionals and insiders believe in LIVN or ZBH?

Which has more risk and volatility, LIVN or ZBH?

Is LIVN or ZBH more profitable?

Which has higher valuation & earnings, LIVN or ZBH?

Does the media favor LIVN or ZBH?

Do analysts prefer LIVN or ZBH?

Summary

How does LivaNova compare to Solventum?

Do analysts recommend LIVN or SOLV?

Which has more volatility and risk, LIVN or SOLV?

Do institutionals and insiders hold more shares of LIVN or SOLV?

Is LIVN or SOLV more profitable?

Which has preferable valuation & earnings, LIVN or SOLV?

Does the media favor LIVN or SOLV?

Summary

How does LivaNova compare to Smith & Nephew SNATS?

Which has better valuation & earnings, LIVN or SNN?

Is LIVN or SNN more profitable?

Do institutionals & insiders have more ownership in LIVN or SNN?

Does the media favor LIVN or SNN?

Do analysts recommend LIVN or SNN?

Which has more volatility & risk, LIVN or SNN?

Summary

How does LivaNova compare to Penumbra?

Do analysts recommend LIVN or PEN?

Which has stronger valuation & earnings, LIVN or PEN?

Is LIVN or PEN more profitable?

Which has more volatility and risk, LIVN or PEN?

Do institutionals and insiders believe in LIVN or PEN?

Does the media prefer LIVN or PEN?

Summary

How does LivaNova compare to Glaukos?

Do insiders & institutionals have more ownership in GKOS or LIVN?

Which has stronger earnings & valuation, GKOS or LIVN?

Do analysts prefer GKOS or LIVN?

Is GKOS or LIVN more profitable?

Does the media refer more to GKOS or LIVN?

Which has more volatility & risk, GKOS or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIVN vs. The Competition

LivaNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools